Sep 012023
Drug Name |
Active Ingredient(s) |
Approval Date |
FDA-Approved Use on Approval Date |
Press Release |
Drug Trials Snapshot |
| Veopoz | pozelimab-bbfg | 8/18/2023 | To treat patients 1 year old and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease | ||
| Sohonos | palovarotene | 8/16/2023 | To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva | Drug Trials Snapshot | |
| Elrexfio | elranatamab-bcmm | 8/14/2023 | To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy | Drug Trials Snapshot | |
| Talvey | talquetamab-tgvs | 8/9/2023 | To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies | ||
| Izervay | avacincaptad pegol | 8/4/2023 | To treat geographic atrophy secondary to age-related macular degeneration | ||
| Zurzuvae | zuranolone | 8/4/2023 | To treat postpartum depression | Press Release | Drug Trials Snapshot |
Sorry, the comment form is closed at this time.